New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
19:03 EDTAGEN, IDIX, ARWR, HAIN, OCLR, IDRA, CHRW, MYGN, MMM, GNWOn The Fly: After Hours Movers
UP AFTER EARNINGS: Myriad Genetics (MYGN), up 14.5%... Genworth (GNW), up 5%... Oclaro (OCLR), up 5.6%. ALSO HIGHER: 3M (MMM), up 2% after the Dow member announced a $12B share repurchase plan... Idenix Pharmaceuticals (IDIX), up 7.3% after investment firm Baupost Group raised its stake in the company to more than 35% from roughly 27% and disclosed it was granted observer rights for meetings of Idenix's board and committees. DOWN AFTER EARNINGS: C.H. Robinson (CHRW), down 6.4%... Hain Celestial (HAIN), down 7.9%. ALSO LOWER: Agenus (AGEN), down 6.2% after announcing a public offering of common stock... Idera Pharmaceuticals (IDRA), down 3.8% after filing to sell common stock and warrants... Arrowhead Research (ARWR), down 3% after reporting a larger-than-expected quarterly loss and filing a $200M mixed securities shelf.
News For MMM;MYGN;GNW;OCLR;IDIX;CHRW;HAIN;AGEN;IDRA;ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 18, 2015
08:52 EDTIDRAIdera Pharmaceuticals provides development update on IMO-9200
Idera Pharmaceuticals announced the achievement of key development milestones for its product candidate IMO-9200, an antagonist of Toll-like receptors, or TLRs, 7, 8 and 9. Specifically, the company reported top-line data from a Phase 1 clinical trial of IMO-9200 in healthy subjects and announced the presentation of new preclinical data for IMO-9200 in models of inflammatory bowel disease, or IBD, at the 2015 Digestive Disease Week Conference, or DDW, in Washington, DC. In the placebo-controlled Phase 1 clinical trial in 30 healthy subjects, IMO-9200 was administered by subcutaneous injection at escalating single-dose levels of 0.1, 0.3, and 0.5 mg/kg. In the multiple dose cohort, a dose of 0.5 mg/kg/week for four weeks was also evaluated. All dose regimens were well tolerated, with no serious adverse events related to IMO-9200 treatment reported. There were no patterns of laboratory or other safety parameters suggestive of any related adverse treatment effect. Additionally, new preclinical data for IMO-9200 were presented on Saturday, May 16 at the 2015 Digestive Disease Week Conference. The poster presentation, entitled "Targeting Innate Immune Receptors to Treat Inflammatory Bowel Disease: Activity of Oral IMO-9200, an Antagonist of TLRs 7, 8, and 9 in Mouse Models of Colitis," provided results from two mouse models of colitis. These results demonstrated the potential of orally dosed IMO-9200 as a treatment for inflammatory bowel disease, which includes Crohn's disease, or CD, and ulcerative colitis.
07:19 EDTMMMElectric Products Group to hold a conference
EPG 2015 is being held in Longboat Key, Florida on May 18-20 with webcasted company presentations to begin on May 18 at 7:30 am; not all company presentations may be webcasted. Webcast Link
May 15, 2015
10:28 EDTMYGNMAC updates positive for NanoString, Myriad, Invitae, QIAGEN, says Leerink
Leerink said that coverage updates posted yesterday by Medicare Administrative Contractors were favorable for NanoString (NSTG), Myriad Genetics (MYGN), Invitae (NVTA) and QIAGEN (QGEN). The firm has Outperform ratings on NanoString and Invitae and Market Perform rating on the other two stocks listed.
10:20 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP RAX KING AOL WPZ RL Z MBI
07:09 EDTMYGNMyriad Genetics presents clinical data for Prolaris test
Myriad Genetics presented clinical data for its Prolaris test at the 2015 American Urological Association, or AUA, Annual Meeting being held May 15-19 in New Orleans, La. The results highlighted and underscored the significant ability of the Prolaris test to help physicians improve care for men diagnosed with prostate cancer. In this pioneering study, Myriad presented important new clinical validation data that establishes an active surveillance, or AS, threshold for men with localized prostate cancer. Specifically, the AS threshold is a composite of the Prolaris test score and clinicopathologic features. In the validation data featured at AUA, the pre-defined AS threshold was evaluated in 765 conservatively managed men, and the clinical endpoint was 10-year risk of prostate cancer mortality. The results showed that at the AS threshold, the predicted 10-year survival rate of prostate cancer patients was 97%. Conversely, there was a three percent risk of 10-year, prostate-specific mortality. Importantly, however, there were no observed prostate cancer-specific deaths over 10 years among men whose scores fell below the AS threshold. Additionally, a separate analysis of 4,218 patients was performed to determine what percentage of patients who were clinically tested with Prolaris would be candidates for active surveillance based on the validated AS threshold. Of this commercial cohort, 36% qualified for active surveillance based on their clinical features alone. However, when the Prolaris test was added to the clinical risk assessment, 60% of these patients fell below the AS threshold, representing a significant increase in the total number of candidates who may be eligible for active surveillance.
May 14, 2015
10:56 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
07:10 EDTAGENAgenus announces presentation at ASCO highlighting Phase 2 Prophage data
Subscribe for More Information
May 13, 2015
18:47 EDTMYGNMyriad Genetics to present data from 19 studies at 2015 ASCO meeting
Subscribe for More Information
13:41 EDTAGENAgenus to host research and development day
Subscribe for More Information
11:08 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
07:13 EDTCHRWBofA/Merrill to hold a conference
2015 Transportation Conference is being held in Boston on May 13-14.
May 12, 2015
10:45 EDTMMMAnalyst says Pall deal may spark more life sciences M&A
Subscribe for More Information
10:16 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NDLS WTW FUEL AOL LC NLNK ZU CYBR ARWR HZNP
09:51 EDTMMMPall Corp. could be precursor to more Life Science deals, says Janney Capital
After The Wall Street Journal said Pall Corp. (PLL) is nearing a possible sale, naming Thermo Fisher (THO) and Danaher (DHR) as potential suitors, Janney Capital said it thinks dealmaking in the Life Sciences space won't stop with Pall, listing Repligen (RGEN), Bio-Techne (TECH) and VWR (VWR) as others in the industry that could see strategic bids emerge. The firm added that it expects that GE (GE), 3M (MMM), and private equity firms would also be involved in bidding in deals in the space.
07:48 EDTGNWStandard & Poor's to hold a summit
Subscribe for More Information
07:37 EDTCHRWOppenheimer to hold a conference
10th Annual Industrial Growth Conference is being held in New York on May 12-13 with webcasted company presentations to begin on May 12 at 8:15 am; not all company presentations may be webcasted. Webcast Link
May 11, 2015
18:29 EDTMYGNAffordable Care Act guidance says insurers must cover BRCA1, BRCA2 testing
The United States Department of Labor issued updated Affordable Care Act guidance, which mandates that health insurers must cover testing for breast and ovarian cancer through analysis of the BRCA1 and BRCA2 genes. Myriad (MYGN), Foundation Medicine (FMI), and Genomic Health (GHDX) compete in the genetic testing space. Reference Link
16:09 EDTARWRArrowhead reports Q2 EPS (51c), consensus (34c)
Reports Q2 revenue $43,750, consensus $110,000.
07:38 EDTIDRAIdera Pharmaceuticals reports Q1 EPS (12c), consensus (11c)
Subscribe for More Information
05:20 EDTGNWGenworth Financial announces sale of portion of interest in Genworth Australia
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use